NVO climbs over 2% after unveiling larger buyback plans and robust technical trends

Traders Union
All News
Financial News
Novo nordisk surges 2.04% today

Highlights

Novo Nordisk launched a new share buyback program, targeting up to DKK 11.2 billion in B shares through February 2027.
The company is expanding its clinical pipeline with a new Phase 3 trial in heart failure and obesity, deepening its focus in cardiometabolic care.
Novo Nordisk shares exhibit sustained bullish momentum, with technical indicators signaling an 80%+ probability of further upside toward the $52.94 resistance.

Share repurchase expansion and new trial drive investor optimism

Novo Nordisk has advanced its ongoing share repurchase initiatives, announcing new plans to buy back B shares for up to DKK 11.2 billion through February 2027. The company is progressing with a DKK 15 billion repurchase program over 12 months and has already acquired approximately 23.98 million B shares for more than DKK 6.2 billion as of July 10, 2026. Novo Nordisk is also broadening its clinical development efforts with a new Phase 3 trial in heart failure and obesity, marking its expansion into wider cardiometabolic care.

Anton Kharitonov, expert at Traders Union, notes the rally is primarily driven by an aggressive share repurchase plan rather than underlying operational improvements. He sees the price extended above major moving averages, which can attract short-term momentum traders, but points to warnings in overbought readings. Kharitonov observes that the 50-day average remains below the 200-day, hinting at hidden technical fragility. He warns that near-term volatility and a tight expected range suggest limited upside before consolidation or reversal is likely. "Investors should be wary of chasing strength at these levels, as prolonged overbought conditions rarely persist without a corrective pullback," Kharitonov concludes.

Viktoras Karapetjanc, expert at Traders Union, highlights Novo Nordisk's robust buyback program as a clear vote of confidence from management. He sees broadening clinical development and strong institutional flows as pillars for further upside. Karapetjanc stresses that the bullish structure remains intact as price holds well above all key moving averages with momentum indicators in support. He anticipates further growth should resistance at $52.94 give way. "I see this setup as offering multiple opportunities for continuation trades, with the outlook remaining decidedly positive in the near term," Karapetjanc states.

Strong momentum and overbought signals as stock tests resistance

Novo Nordisk trades above all key moving averages, with the current price at $51.59 well above the 20-day ($47.86), 50-day ($45.82), and 200-day ($47.44) levels. This alignment signals confirmation of bullish short-, medium-, and long-term trends, though a bearish longer-term alignment of the 50-day versus the 200-day average is noted. The near-term ceiling stands at $52.94 with support at the recent high of $50.99. Momentum signals remain strong, with the MACD and ADX both forecasting buy conditions. The RSI sits at 67.58 with a "Buy" bias, while the CCI and BBP indicate overbought territory, and the Stochastic RSI reinforces a strong buy reading. Intraday volatility is at 1.47%, with price action near the session high, reflecting sustained bullish momentum.

Earlier, analysts noted that ongoing share buybacks and robust demand for GLP-1 therapies had reinforced Novo Nordisk’s positive outlook amid strong technical momentum. The current advance in the company’s repurchase program and expansion into new clinical trials further solidify this constructive stance, with traders now watching for a decisive move above $52.94 to confirm continued upside.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.